Leigh Zawel - Aug 9, 2021 Form 4/A - Amendment Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Officer
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Aug 9, 2021
Transactions value $
-$752,850
Form type
4/A - Amendment
Date filed
8/26/2021, 07:20 PM
Date Of Original Report
Aug 11, 2021
Next filing
Aug 26, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale -$517K -19.5K -13.02% $26.52 130K Aug 9, 2021 Direct F1, F2
transaction CGEM Common Stock Sale -$46.1K -1.7K -1.31% $27.11 129K Aug 9, 2021 Direct F1, F3
transaction CGEM Common Stock Sale -$50.5K -1.91K -1.48% $26.50 127K Aug 10, 2021 Direct F1, F4
transaction CGEM Common Stock Sale -$87.2K -3.19K -2.52% $27.34 123K Aug 10, 2021 Direct F1, F5
transaction CGEM Common Stock Sale -$51.8K -1.82K -1.47% $28.49 122K Aug 10, 2021 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.98 to $26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.98 to $27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.95 to $26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.95 to $27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.07 to $28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Scientific Officer, Small Molecules This amended Form 4 is being filed to include an explanatory note that the reported sales were made pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.